Raphael Dahmen

995 total citations · 1 hit paper
11 papers, 755 citations indexed

About

Raphael Dahmen is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Raphael Dahmen has authored 11 papers receiving a total of 755 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Surgery and 3 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Raphael Dahmen's work include Diabetes Management and Research (8 papers), Pancreatic function and diabetes (6 papers) and Diabetes Treatment and Management (6 papers). Raphael Dahmen is often cited by papers focused on Diabetes Management and Research (8 papers), Pancreatic function and diabetes (6 papers) and Diabetes Treatment and Management (6 papers). Raphael Dahmen collaborates with scholars based in Germany, United States and Italy. Raphael Dahmen's co-authors include R. H. A. Becker, Tim Heise, Karin Bergmann, Anne Lehmann, Thomas Jax, Ronald Schmidt, Geremia B. Bolli, David R. Powell, Ronan Roussel and Nassr Nama and has published in prestigious journals such as Diabetes Care, Diabetes Obesity and Metabolism and Cardiovascular Diabetology.

In The Last Decade

Raphael Dahmen

11 papers receiving 731 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

2014 292 citations R. H. A. Becker, Raphael Dahmen et al. Diabetes Care profile →

Peers

Countries citing papers authored by Raphael Dahmen

Since Specialization

Citations

This map shows the geographic impact of Raphael Dahmen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raphael Dahmen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raphael Dahmen more than expected).

Fields of papers citing papers by Raphael Dahmen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raphael Dahmen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raphael Dahmen. The network helps show where Raphael Dahmen may publish in the future.

Co-authorship network of co-authors of Raphael Dahmen

This figure shows the co-authorship network connecting the top 25 collaborators of Raphael Dahmen. A scholar is included among the top collaborators of Raphael Dahmen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raphael Dahmen. Raphael Dahmen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study 2022 ·Diabetes Care ·Maximilian Posch, (unknown), Ele Ferrannini, David R. Powell, Phillip Banks, Suman Wason, Raphael Dahmen	19
2	Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF 2021 ·Cardiovascular Diabetology ·David Bode, (unknown), Paulina Wakula, (unknown), Uwe Primeßnig, Nicola Beindorff, David R. Powell, Raphael Dahmen, Hartmut Ruetten, Christian U. Oeing, Alessio Alogna, Daniel Messroghli, Burkert Pieske, Frank R. Heinzel, Felix Hohendanner	89
3	Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes 2017 ·Diabetes & Metabolism ·Timothy S. Bailey, Jeremy Pettus, Ronan Roussel, (unknown), (unknown), Nassr Nama, Oliver Klein, G. B. Bolli, Raphael Dahmen	69
4	A Population Dose-Response Model for Inhaled Technosphere Insulin Administered to Healthy Subjects 2017 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Raphael Dahmen, Anders Boss, Robert De Jager, (unknown), R Baughman, Thomas Klabunde	3
5	Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator 2016 ·Diabetes Technology & Therapeutics ·R. Visentin, (unknown), Robert De Jager, Raphael Dahmen, Anders Boss, (unknown), Chiara Dalla Man, Claudio Cobelli, Thomas Klabunde	30
6	Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes 2016 ·Journal of Diabetes Science and Technology ·(unknown), Lori Berard, Claire Brulle-Wohlhueter, (unknown), Raphael Dahmen, Irene Nowotny, David C. Klonoff	9
7	New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1 breakdown → 2014 ·Diabetes Care ·R. H. A. Becker, Raphael Dahmen, Karin Bergmann, Anne Lehmann, Thomas Jax, Tim Heise	292
8	Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes 2014 ·Diabetes Obesity and Metabolism ·Masanari Shiramoto, Takashi Eto, S. Irie, (unknown), Lenore Teichert, J. Tillner, Yoshinori Takahashi, Masayoshi Koyama, Raphael Dahmen, Tim Heise, R. H. A. Becker	76
9	Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml 2014 ·Diabetes Obesity and Metabolism ·(unknown), Ronald Schmidt, Karin Bergmann, Raphael Dahmen, R. H. A. Becker	80
10	Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes 2012 ·Diabetes Care ·Geremia B. Bolli, (unknown), Ronald Schmidt, (unknown), Raphael Dahmen, Tim Heise, R. H. A. Becker	81
11	Hormonal inducibility of liver-specific enzymes in cultured rat embryos. 1986 ·PubMed ·Pieter J. Westenend, Raphael Dahmen, Robert Charles, (unknown)	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact